Tag Archives: NASDAQ:KRYS

Chardan Capital Keeps Their Buy Rating on Krystal Biotech (KRYS)

Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Krystal Biotech (KRYS – Research Report) today and set a price target of $115.00. The company’s shares closed last Tuesday at $47.63. According to TipRanks.com, Amusa is a 5-star analyst

Krystal Biotech (KRYS) Received its Third Buy in a Row

After William Blair and H.C. Wainwright gave Krystal Biotech (NASDAQ: KRYS) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Gbola Amusa reiterated a Buy rating on Krystal Biotech today and set a

Analysts Offer Insights on Healthcare Companies: Krystal Biotech (NASDAQ: KRYS) and BioCryst (NASDAQ: BCRX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Krystal Biotech (KRYS – Research Report) and BioCryst (BCRX – Research Report). Krystal Biotech (KRYS) In a report released today, Joseph Pantginis from

William Blair Sticks to Their Buy Rating for Krystal Biotech (KRYS)

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Krystal Biotech (KRYS – Research Report). The company’s shares closed last Tuesday at $42.82. According to TipRanks.com, Prasad is a 5-star analyst with an average

Krystal Biotech (KRYS) Gets a Buy Rating from William Blair

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Krystal Biotech (KRYS – Research Report). The company’s shares closed last Monday at $45.00. According to TipRanks.com, Prasad is a 5-star analyst with an average

Krystal Biotech (KRYS) Gets a Buy Rating from Chardan Capital

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Krystal Biotech (KRYS – Research Report), with a price target of $100.00. The company’s shares closed last Monday at $49.82. According to TipRanks.com, Amusa is